Last reviewed 2026-04-20 · How we verify

Orpizin (CHLORAZANIL)

Phase 2 active Small molecule

Orpizin (generic name: CHLORAZANIL) is a drug. It is currently in Phase 2 development for Cobalamin deficiency, Pernicious anemia, Prevention of Vitamin B12 Deficiency.

Orpizin works by inhibiting the breakdown of Cobalamin, allowing it to be absorbed and utilized by the body.

Orpizin, also known as Chlorazanil, is a small molecule modality developed for the treatment of Cobalamin deficiency, Pernicious anemia, and Prevention of Vitamin B12 Deficiency. However, due to the lack of available information, its target and drug class remain unknown. The commercial status of Orpizin is unclear, with no information available on its patent status or generic manufacturers. Further research is needed to determine its safety profile and pharmacokinetic properties. As a result, its use should be approached with caution.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CHLORAZANIL
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Think of it like a shield that protects Cobalamin from being destroyed, allowing it to be used by the body to make red blood cells and maintain healthy nerve function.

Approved indications

Cobalamin deficiency
Pernicious anemia
Prevention of Vitamin B12 Deficiency

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Orpizin CI brief — competitive landscape report
Orpizin updates RSS · CI watch RSS

Frequently asked questions about Orpizin

What is Orpizin?

Orpizin (CHLORAZANIL) is a Small molecule drug, indicated for Cobalamin deficiency, Pernicious anemia, Prevention of Vitamin B12 Deficiency.

How does Orpizin work?

Orpizin works by inhibiting the breakdown of Cobalamin, allowing it to be absorbed and utilized by the body.

What is Orpizin used for?

Orpizin is indicated for Cobalamin deficiency, Pernicious anemia, Prevention of Vitamin B12 Deficiency.

What is the generic name of Orpizin?

CHLORAZANIL is the generic (nonproprietary) name of Orpizin.

What development phase is Orpizin in?

Orpizin is in Phase 2.

Therapeutic area: All drugs in Hematology
Indication: Drugs for Cobalamin deficiency
Indication: Drugs for Pernicious anemia
Indication: Drugs for Prevention of Vitamin B12 Deficiency

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing